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Abstract
Background: White matter hyperintensities (WMHs) are commonly seen on in brain imaging and are associated
with stroke and cognitive decline. Therefore, they may provide a relevant intermediate outcome in clinical trials.
WMH can be measured as a volume or visually on the Fazekas scale. We investigated predictors of WMH
progression and design of efficient studies using WMH volume and Fazekas score as an intermediate outcome.
Methods: We prospectively recruited 264 patients with mild ischaemic stroke and measured WMH volume, Fazekas
score, age and cardiovascular risk factors at baseline and 1 year. We modelled predictors of WMH burden at 1 year
and used the results in sample size calculations for hypothetical randomised controlled trials with different analysis
plans and lengths of follow-up.
Results: Follow-up WMH volume was predicted by baseline WMH: a 0.73-ml (95% CI 0.65–0.80, p < 0.0001) increase
per 1-ml baseline volume increment, and a 2.93-ml increase (95% CI 1.76–4.10, p < 0.0001) per point on the Fazekas
scale. Using a mean difference of 1 ml in WMH volume between treatment groups, 80% power and 5% alpha,
adjusting for all predictors and 2-year follow-up produced the smallest sample size (n = 642). Other study designs
produced samples sizes from 2054 to 21,270. Sample size calculations using Fazekas score as an outcome with the
same power and alpha, as well as an OR corresponding to a 1-ml difference, were sensitive to assumptions and
ranged from 2504 to 18,886.
Conclusions: Baseline WMH volume and Fazekas score predicted follow-up WMH volume. Study size was smallest
using volumes and longer-term follow-up, but this must be balanced against resources required to measure
volumes versus Fazekas scores, bias due to dropout and scanner drift. Samples sizes based on Fazekas scores may
be best estimated with simulation studies.
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Background
White matter hyperintensities (WMHs) are lesions in
the white matter of the brain visible on magnetic reson-
ance imaging (MRI). They are common and associated
with stroke [1, 2], dementia [3, 4] and physical disability
[5]. There is increasing interest in using WMH as an
outcome in trials investigating cerebral small vessel dis-
ease and associated diseases such as stroke and dementia
[4]. However, the mechanism for the development of
WMH is not fully understood, and research, including
randomised controlled trials (RCTs), into the role of
modifiable risk factors such as hypertension, diabetes,
smoking and hyperlipidaemia is ongoing [6].
Measurement of WMH volumes is not trivial, and
there is not yet a consensus on how it should be done
[7]. It is labour- and resource-intensive, requiring much
time from staff with specialist image analysis skills.
Fazekas scores are much easier to obtain as they may be
read from brain scans within a few minutes by individ-
uals with appropriate training. The Fazekas scale gives
scores ranging from 0 to 3 each for periventricular white
matter and deep white matter, which can be summed to
give a total score from 0 to 6, with lower scores indicat-
ing less WMH burden.
Any trial using WMH as an outcome should adjust for
important predictor variables such as baseline WMH
and age. Also, prediction of WMH for an individual pa-
tient is difficult because there is much variability in
WMH progression between patients [8]. However, previ-
ously published WMH sample size calculations have
used unadjusted estimates [9, 10]. Therefore, we studied
the predictors of WMH in a high-risk population,
namely patients with mild stroke, in whom WMHs are
an adverse prognostic marker [11, 12] and who would
therefore benefit from interventions to reduce WMH
progression. We examined ways, using study design, co-
variate adjustment and statistical analysis, to reduce
sample size for clinical trials of WMH progression. We
present our results on predictors of WMH and sample
size calculations for hypothetical RCTs.
Methods
Patients and recruitment
We prospectively recruited consecutive patients aged
over 18 years with a recent first symptomatic mild is-
chaemic lacunar or cortical stroke who presented to our
hospital stroke service. All strokes were non-disabling,
not requiring hospitalisation, and 98% of patients had
scores of 4 or less on the National Institutes of Health
Stroke Scale [13]. Patients with stroke due to genetic
causes or dissection of the carotid or vertebral artery
were excluded. The final diagnosis of stroke was reached
as described below. All patients were able to give con-
sent and undergo MRI at presentation. Patients with
severe stroke, MRI contraindications or haemorrhagic
stroke were excluded. All participants involved in the
study gave written informed consent, and the study was
approved by the Lothian Research Ethics Committee
(reference 09/S1101/54).
Assessments
Demographic and clinical history and examination data
were collected at presentation by a trained stroke phys-
ician. Blood pressure was measured with clinic sphyg-
momanometers. Patients underwent carotid imaging,
blood tests and other investigations as required for
stroke.
Patients underwent diagnostic brain MRI at presenta-
tion on a 1.5-Tesla MRI scanner (Signa HDxt; GE
Healthcare, Milwaukee, WI, USA) using an 8-channel
phased-array head coil. Diagnostic MRI scans acquired
at presentation included axial T2-weighted (repetition
time [TR]/[TE] 6000/90 ms, 24 × 24-cm field of view
[FoV], 384 × 384 periodically rotated overlapping parallel
lines with enhanced reconstruction acquisition, 1.5 aver-
ages, 28 × 5-mm slices, 1-mm slice gap), axial fluid-
attenuated inversion recovery (TR/TE/inversion time
[TI] 9000/153/2200 ms, 24 × 24 cm FoV, 384 × 224 ac-
quisition matrix, 28 × 5-mm slices, 1-mm slice gap),
gradient echo (TR/TE 800/15 ms, 20-degree flip
angle, 24 × 18-cm FoV, 384 × 168 acquisition matrix, 2
averages, 28 × 5-mm slices, 1-mm slice gap), sagittal
three-dimensional T1-weighted (inversion recovery-
prepared spoiled gradient echo TR/TE/TI 7.3/2.9/500
ms, 8-degree flip angle, 330 × 214.5-cm FoV, 256 × 146
acquisition matrix, 100 × 1.8-mm slices) and diffusion
tensor MRI (single-shot echo planar imaging with 30 dif-
fusion directions [b = 1000 s/mm] and 2 × b0 acquisitions,
TR/TE 7700/82 ms, 24 × 24-cm FoV, 128 × 128 acquisi-
tion matrix, 28 × 5-mm slices, 1-mm slice gap).
Patients were asked to return for MRI at 1 year on the
same scanner with the same sequences. Throughout the
study, the scanner underwent careful daily quality assur-
ance to check that performance remained within tight
limits.
Final diagnosis of stroke and its subtype
The final diagnosis of stroke was determined by an ex-
pert panel of stroke physicians, neurologists and neuro-
radiologists who considered all available clinical and
imaging information and decided if the diagnosis was
stroke, and, if stroke, then whether it was of the lacunar
or cortical subtype according to the Oxfordshire
Community Stroke Project classification [14]. Where the
clinical syndrome differed from the imaging stroke sub-
type, as occurs in about 15% of mild stroke cases [15],
the imaging subtype was used; where there was no index
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event visible on imaging (as occurs in about 30% of mild
stroke cases [16]), the clinical syndrome was used.
Image processing
The MRI scans were scored according to the method of
Fazekas [17] and for lacunes; perivascular spaces [18];
microbleeds [18]; mineral deposition [19]; the index
stroke type; any old infarcts or haemorrhages on presen-
tation and 1-year scans; and any new infarcts, haemor-
rhages and changes in WMH at 1 year. This scoring was
done with a standard pro forma and validated scales by
an expert neuroradiologist who was blinded to clinical
details [18, 20–24]. The Fazekas scores from baseline
and 1-year follow-up images were rated blinded to each
other and to clinical information.
The images were also processed using a validated,
semi-automated, multispectral image-processing method
to determine intracranial, cerebrospinal fluid, whole
brain, grey matter, white matter and WMH volumes
[25]. In a Bland-Altman analysis measuring WMH vol-
ume, this method has a mean difference of 0.38 ml and
limits of agreement −2.93 to 3.69 ml [26, 27]. This
method fuses combinations of sequences mapped in the
colour spectrum and separates tissues according to clus-
ters of signalling. Infarcts (index, old, new during follow-
up) were masked from the WMH tissue by manual tra-
cing to avoid contaminating WMH measurements [28].
Statistical analysis
We used the following hypothesis-driven predictors in
simple and multiple linear regression with follow-up
WMH volume as an outcome:
 Baseline WMH volume
 Age at initial recruitment
 Final diagnosis of lacunar versus cortical stroke
subtype
 Fazekas score (periventricular plus deep white
matter) [21]
 Hypertension (blood pressure ≥140/90 mmHg)
 Mean arterial pressure (MAP) (2 × diastolic + systolic
blood pressure)/3
 Pulse pressure (PP) (systolic − diastolic blood
pressure)
 Diabetes (fasting blood glucose ≥6.1 mmol/L)
 Smoking status (non-smoker for at least 1 year
versus current and recent smoker)
 Hyperlipidaemia (total cholesterol >5.0 mmol/L)
We did not choose predictors on the basis of statistical
significance, because this can lead to unreliable results
[29]. We tested for differences between patients with
and without follow-up imaging at 1 year with t tests for
continuous variables and chi-square tests for categorical
variables. We repeated analyses with WMH volume nor-
malised with respect to intracranial volume and obtained
nearly identical results (data not presented).
We used our results to conduct sample size calcula-
tions for hypothetical studies. The sample size calcula-
tions are for an RCT with the hypothesis that the
treatment will stabilise WMH volumes and normal pro-
gression is 1 ml over the course of 1 year (as seen in our
data), with the standard sample size calculation require-
ments of 80% power and 5% alpha (two-sided), and with
a simple comparison of WMH volumes in the control
and treatment groups by linear regression. We then
changed the analysis plan to include adjustment for the
predictors and adjusted the sample size accordingly [30].
Also, we replaced WMH volumes with Fazekas scores
as the outcome variable because they are commonly
used to assess WMH disease, and then we recalculated
the sample sizes. We wanted the Fazekas sample size
calculations to be based on the same degree of white
matter disease progression as was used in the WMH
volume sample sizes. This way the Fazekas sample size
estimates could be based on the same underlying change
in WMH, even if this change was measured with Fazekas
scores rather than WMH volumes. We therefore needed
to estimate the change in Fazekas score equivalent to the
1-ml change used in the WMH volume calculations. We
used ordinal logistic regression because Fazekas scores are
ordinal data, and we estimated the odds ratio (OR) associ-
ated with increasing Fazekas score for an increase of 1 ml
in WMH volume and used this estimate (OR 1.21, 95% CI
1.16–1.25) in the sample size calculations.
We applied Whitehead’s formula for the logistic re-
gression sample sizes for Fazekas scores. Sample size cal-
culation for logistic regression with baseline adjustment
is complex with often untestable assumptions, and it
often increases the sample size. One of the assumptions
of Whitehead’s formula is that the underlying treatment
versus control OR for each baseline category (here,
Fazekas group) is the same. This is unlikely to be true in
many cases, and Whitehead recommends ‘to try out
various scenarios to evaluate the robustness of a pro-
posed design’ [31]. We present below, for interest only, a
sample size calculation for a proportional odds model
with baseline adjustment, with the caveat that our data
would be unlikely to have a constant OR in treatment
versus control groups in all baseline categories. If a sam-
ple size calculation were required for a real RCT using
Fazekas score as the outcome, we would recommend
simulation to explore assumptions regarding the OR and
the effect of predictors. However, we do not present a
full simulation for a sample size calculation, because it is
likely to be sensitive to assumptions and selection of
pre-specified predictors [32]. Therefore, the results of a
simulation for a hypothetical study are unlikely to be
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widely applicable and may mislead triallists with regard
to required sample size. However, the rms package in R
[33] has been used for sample size simulation for ordinal
logistic regression in the context of stroke, and we rec-
ommend this as a template, in particular for the explor-
ation of the proportional odds assumption [34, 35]
Last, we also calculated the sample size for a hypothet-
ical RCT with 1 year follow-up where the treatment
group’s Fazekas score would not change but the control
group’s would increase as in our dataset—an increase of
0.5 in median Fazekas score. This RCT would use the
Wilcoxon rank-sum test to compare median Fazekas
scores in the two groups, with the standard assumptions
of 80% power and 5% alpha. We considered and
rejected using a non-parametric analysis of covariance
(ANCOVA) model to allow for baseline Fazekas ad-
justment in the comparison of medians. There are
several non-parametric ANCOVA models available
[36–38], but our dataset is not representative of the
datasets used to assess the performance of the non-
parametric ANCOVA models, because most (183 of
197) patients’ Fazekas scores did not change between
baseline and follow-up; that is, the data had many
ties, but the non-parametric ANCOVA models were
not developed or tested with data where the majority
of participants did not change.
We used SAS version 9.3 (SAS Institute, Cary, NC,
USA) [39] and R version 2.13.1 [33] software with the
add-on package Hmisc [40] for analysis.
Results
We recruited 264 patients from 10 May 2010 to 24
December 2012, and 190 had imaging data at 1 year.
Of the 74 with no 1-year WMH volumes, 33 declined
to participate, 24 were unwell, 5 had died, 6 had vari-
ous other reasons for not participating and 6 had in-
complete scans that did not allow calculation of
volume data.
Patients who completed follow-up MRI were younger
by 5.7 years than patients who did not have another scan.
MAP, PP and diastolic and systolic blood pressures were
not significantly different between those with and without
follow-up MRI (all estimated differences <0.6 mmHg,
p > 0.73 for all). There was also no significant differ-
ence for stroke subtype, hypertension, diabetes, smoking
status or hyperlipidaemia (p > 0.16 for all). Baseline
Fazekas scores tended to be higher in patients without
follow-up (p = 0.049) (Table 1).
At follow-up, the mean (SD) WMH volume was
23.2 ± 23.3 ml. The mean difference between follow-
up and baseline was an increase of 1.27 ml (95% CI
0.06–2.48, p = 0.040). A total of 124 patients had an
increase (mean increase 5.5 ± 5.8 ml) in WMH volume,
whereas 66 had a decrease (mean decrease 6.6 ± 6.9 ml)
(Fig. 1). The median Fazekas score at follow-up was 3
(IQR 2–4), a non-significant increase of 0.5 from baseline
(2.5; IQR 2–4). There was no statistically significant rela-
tionship between blood pressure and WMH change after
adjustment (Table 2, Fig. 2).
Table 1 Estimated differences between patients with (n = 190) and without (n = 74) follow-up data
Predictor Summary Difference between patients with
versus without follow-up (95% CI)a
p Value
Baseline WMH volume, ml, mean ± SD 22.0 ± 24.8 −4.1 (−10.8 to 2.7) 0.23
Age, years, mean ± SD 65.3 ± 11.3 5.7 (−8.8 to −2.6) 0.0004
MAP, mmHg, mean ± SD 102.8 ± 15.4 0.50 (−3.61 to 4.61) 0.81
PP, mmHg, mean ± SD 63 ± 20.7 −0.45 (−5.88 to 4.98) 0.87
Hypertension, n (%) 142 (74.7) 8.5% (−3.9 to 20.9%) 0.16
Stroke subtype lacunar, n (%) 87 (45.8) 3.9% (−9.4 to 17.2%) 0.57
Smoker (current and recent ex-smokers), n (%) 73 (38.4) −1.9% (−15.1 to 11.4%) 0.78
Diabetes, n (%) 21 (11.1) −1.1% (−9.8 to 7.8%) 0.80
Hyperlipidaemia, n (%) 116 (61.1) 0.2% (−12.9 to 13.4%) 0.97
Fazekas score = 0, n (%) 8 (4.2) 1.5% (−3.2 to 6.2%) Overall p value = 0.049
Fazekas score = 1, n (%) 17 (9.0) −1.9% (−10.0 to 6.3%)
Fazekas score = 2, n (%) 70 (36.8) 8.5% (−3.9 to 20.8%)
Fazekas score = 3, n (%) 24 (12.6) 3.2% (−5.0 to 11.3%)
Fazekas score = 4, n (%) 29 (15.3) 8.5% (−0.8 to 16.2%)
Fazekas score = 5, n (%) 17 (9.0) −8.6% (−18.2 to 1.0%)
Fazekas score = 6, n (%) 25 (13.2) −11.2% (−22.1 to 0.3%)
Abbreviations: MAP Mean arterial pressure, PP Pulse pressure, WMH White matter hyperintensity
a Estimated difference between patients with and without follow-up WMH volume (difference in means for baseline WMH, age, MAP, PP and difference in
percentage for other predictors). A positive number indicates that patients with follow-up had a higher mean or larger proportion
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We expected and checked for collinearity with vari-
ance inflation factors, because MAP, PP and diagnosis of
hypertension are all ways of assessing blood pressure,
and Fazekas score and baseline WMH volume are both
ways of assessing WMH burden. The blood pressure
variance inflation factors were 1.4, 1.6 and 1.2, respect-
ively, for MAP, PP and diagnosis of hypertension, indi-
cating that they are not a source of collinearity.
However, Fazekas score and baseline WMH volume have
variance inflation factors of 3.4 and 3.1, respectively.
This may or may not indicate an acceptable degree of
collinearity to researchers, so the results should be inter-
preted cautiously, though it should be noted that drop-
ping Fazekas score from the model gives similar results.
The predictor that explained most of the variation in
follow-up WMH volume was baseline WMH volume in
both univariate and multivariable analyses (Table 2,
Fig. 1a). Fazekas score was also related. Uncertainty in
the univariate analyses (evidenced by wide CIs) and
changes of directions for some predictors (e.g. diabetes)
were observed. Individual changes in WMH volume
were varied, and WMH decreased in some patients,
stayed the same in some, and increased in others,
reflected in the wide SD. MAP was negatively associated
with WMH progression in adjusted analysis (Table 2), as
suggested in Fig. 1, where there are more patients with
higher starting blood pressure with decreasing WMH.
The sample size calculations for WMH volume were
based on an RCT in which the treatment was hypothe-
sised to stabilise WMH volume as at trial entry by pre-
venting progression of WMH. In the control group,
WMH would increase, as seen in our observational data
at approximately by 1 ml per year, and the WMH vol-
ume SD at follow-up would be 23.3 ml. We then
Fig. 1 a Baseline white matter hyperintensity (WMH) volume versus 1-year follow-up WMH volume. b Each line represents the change for an
individual patient
Table 2 Univariate and multivariable linear regression results. Multivariable estimates are adjusted for all other predictors
Predictor Unadjusted change in WMH volume at 1 year
per unit change in predictor (95% CI)
Unadjusted
p value
Adjusted change in WMH volume at 1 year
per unit change in predictor (95% CI)
Adjusted
p value
Baseline WMH volume, ml 0.88 (0.84 to 0.93) <0.0001 0.73 (0.65 to 0.80) <0.0001
Age 0.91 (0.64 to 1.17) <0.0001 −0.02 (−0.14 to 0.10) 0.75
MAP −0.11 (−0.33 to 0.11) 0.31 −0.10 (−0.19 to −0.02) 0.013
PP 0.19 (0.035 to 0.35) 0.017 0.03 (−0.03 to 0.10) 0.34
Hypertension 4.89 (−2.77 to 12.54) 0.21 −1.40 (−4.06 to 1.26) 0.30
Fazekas score 11.54 (10.43 to 12.65) <0.0001 2.93 (1.76 to 4.10) <0.0001
Stroke subtype 0.88 (−5.83 to 7.58) 0.80 −0.85 (−3.05 to 1.34) 0.44
Smoking status −2.30 (−9.16 to 4.56) 0.51 0.17 (−2.24 to 2.57) 0.89
Diabetes 10.36 (−0.19 to 20.90) 0.054 −1.98 (−5.51 to 1.54) 0.27
Hyperlipidaemia −0.51 (−7.36 to 6.34) 0.88 −1.10 (−3.40 to 1.19) 0.34
Abbreviations: MAP Mean arterial pressure, PP Pulse pressure, WMH White matter hyperintensity
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adjusted the sample size for inclusion of predictors in
the analysis. The R2 values are taken from regression
models with follow-up WMH volume as the outcome,
and they are used to calculate the reduction in sample
size that would happen by including adjustment for pre-
dictors by reducing the unexplained variability in out-
come. We then recalculated the sample size for a 2-ml
difference between active and control groups and for
2 years of follow-up, assuming the same per-year in-
crease in WMH. The sample size calculations for
Fazekas score are based on our baseline and follow-up
data percentages of patients in each category.
If the RCT had allowed for 2 years of follow-up and
with the same assumptions so that the control group
WMH volume would increase by 2 ml, then the sample
size per group would be 2128 (4256 in total). Adjust-
ment for all predictors reduces this to 205 per group
(410 in total) before allowing for dropouts (Table 3).
If Fazekas score were the outcome variable, then sam-
ple sizes would increase by a factor of 5.04 between not
adjusting and adjusting for baseline Fazekas score,
assuming a constant OR for treatment versus control in
all baseline Fazekas categories. This assumption is not
likely to be true and would need to be explored with a
simulation study. Other predictors would inflate the
sample size less, given the same assumption (Table 3).
The large sample size for the comparison of medians is
a result of most patients’ Fazekas scores not changing
over the course of 1 year.
Discussion
WMH volumes are linked to cognitive decline, stroke,
dementia and death. Although their causes have not yet
been fully ascertained, treatment of risk factors such as
blood pressure may limit their progression. These inter-
ventions are being tested in ongoing trials. We studied a
well-defined patient sample with mild non-disabling is-
chaemic stroke, a group likely to be of interest to re-
searchers in stroke and dementia. The WMH volumes
were measured carefully with a well-developed method-
ology. In our observational cohort of patients followed
for 1 year, there was wide variation in WMH volume
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Fig. 2 Change in white matter hyperintensity (WMH) (follow-up minus baseline) versus blood pressure
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change from patient to patient, making prediction for in-
dividual patients difficult. Roughly one-third of our sam-
ple showed a decrease in WMH, and two-thirds showed
an increase. The extent of change also varied widely,
with a mean change of 1.27 ml but a range from
−32.0 ml to +29.1 ml. The predictor that explained most
of the variation in WMH progression was WMH volume
or Fazekas score at presentation.
Previous estimations of average rates of progression of
WMH were similar to ours at about 1 ml per year, but
they did not seem to identify the relatively large propor-
tion whose WMH decreased [8, 9]. This may reflect the
fact that other populations, such as community-dwelling
older subjects as in the Leukoaraiosis and Disability
Study [10] or the Austrian Stroke Prevention Study [41],
may be less variable than patients presenting with an
acute disease such as stroke.
Researchers seeking to undertake RCTs of treatment
to prevent WMH progression need to be aware that the
variation in WMH volumes, at least in stroke patients,
can lead to prohibitively large sample sizes unless an ef-
ficient study design is used. Fortunately, making RCTs
more efficient need not be difficult. Analyses that use a
baseline measurement as a predictor are known to be
more efficient than studies comparing follow-up mea-
surements only, or even those that use difference be-
tween baseline and follow-up [42–44]. Our calculations
for hypothetical studies show that it is possible to re-
duce the required sample size by more than 90% by
including some routinely collected data and a baseline
measurement. Increasing duration of follow-up to 2 years
also helps reduce sample size but increases cost per pa-
tient substantially as well as the number of dropouts.
However, a trial of 1642 patients (followed over 1 year,
2054 allowing for dropouts) is a massive undertaking,
especially if all must have baseline and follow-up MRI
and all images must be analysed for WMH volume,
which has to be done centrally by trained operators, in-
cluding careful exclusion of the index and any old stroke
lesions. Of note, 74 (28%) of 264 in our cohort did not
have MRI at 1 year. Failure to have repeat MRI is not
uncommon in observational studies and trials.
We did not allow for a range of dropout rates, and we
present data for only a 20% per year dropout rate. This
(and other rates) of course increases the required sample
size. Here, just under one-third (28%) did not have 1-
year MRI. Although this might have been different in an
RCT (rather than an observational study), we have no
evidence that patients are more likely to comply with
imaging in trials. Moreover, 29 (39%) of 74 patients who
dropped out did so for reasons of health, which is likely
to be a source of bias; it seems reasonable to suppose
that people with worse general health have less healthy
white matter and hence more WMH progression. This
bias would have a greater effect in studies with longer
follow-up, because dropout is generally greater in long-
term studies. The attractive sample size estimate for the
2-year study needs to be balanced against this bias. Stat-
istical methods for dealing with missing data generally
assume that the data are missing at random. Although
Table 3 Sample sizes for hypothetical randomised controlled trials with different analysis plans/outcome variable
Predictors included in RCT analysis Outcome variable at
1-year follow-upa
Sample size
(n per group)
Total sample
size
Allowance for 20%
dropout
Treatment group only (assumed difference 1 ml) WMH volume 8508 17,016 21,270
Treatment group + baseline WMH volume (R2 = 0.88) WMH volume 987 1974 2468
Treatment group + age (R2 = 0.19) WMH volume 6872 13,744 17,180
Treatment group + baseline Fazekas score (R2 = 0.69) WMH volume 2628 5256 6570
Treatment group + all predictors used in multivariable analysis (R2 = 0.90) WMH volume 821 1642 2054
Treatment group + all predictors used in multivariable analysis (R2 = 0.90)
and 2-year follow-up
WMH volume 205 410 642b
Treatment group only (assumed OR 1.2) Fazekas score 1499 2998 3748
Treatment group only (assumed OR 1.25, upper 95% CI) Fazekas score 1001 2002 2504
Treatment group only (assumed OR 1.16, lower 95% CI) Fazekas score 2262 4524 5656
Treatment group + baseline Fazekas (multiplierc 5.04) Fazekas score 7554 15,108 18,886
Treatment group + baseline hypertension (multiplierc 1.00057) Fazekas score 1500 3000 3750
Treatment group + baseline age (multiplierc 1.012) Fazekas score 1515 3030 3788
Treatment group only (median increase 0.5) Fazekas score 87,216 174,432 218,040
RCT Randomised controlled trial, WMH White matter hyperintensity
a Except for second multivariate sample size estimate, where 2-year follow-up was used
b A 20% dropout per year was used for the 2-year follow-up (i.e., a total dropout rate of 36%)
c The multiplier is the number by which the base sample size must be multiplied to allow for the inclusion of an additional predictor in the analysis without loss
of power; the base sample size is that for an analysis with Fazekas score as outcome and treatment group as the only predictor
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the methodology of dealing with data that are not miss-
ing at random is developing, and although it is possible
that data more readily obtainable at follow-up could be
used in multiple imputation, any results would need to
be interpreted very cautiously. In particular, the sensitiv-
ity of results to assumptions about the relationship of
missingness and observed data would require careful ex-
ploration. Additionally, the longer the follow-up, the
greater the risk of genuine changes in MRI scanner per-
formance or in scanner replacement, which could inflate
variance and further alter the detection of WMH. Fi-
nally, 6 (8%) of the 74 subjects without follow-up MRI
data actually had the scan, but their data were unsuitable
for WMH volume measurement because of patient
movement within the scanner or completing only part of
the scan.
Over 10% (33 of 264) of patients (45% of the 74 who
did not have 1-year MRI) did not have follow-up WMH
volume data because they found the first MRI scan un-
pleasant. Although careful screening of patients with
claustrophobia and other contraindications is essential,
it is not possible to predict which patients will decline
follow-up because it involves MRI.
We know that the patients with follow-up were youn-
ger and had lower Fazekas scores than the entire base-
line group. Although we adjusted for age, Fazekas score
and other predictors, the baseline and follow-up groups
may differ in other ways that we have not been able to
account for.
We have not allowed for the effects of between-
scanner variation on measurement of WMH volume,
but large trials (even to get the minimum number of 642
patients calculated here) require multicentre participa-
tion, which inevitably requires use of different scanners
and introduces between-scanner variation. Whether the
Fazekas score (or other visual scores) are less susceptible
to between-scanner variation is not known and would
be an obvious target for testing to inform future trials in
stroke and dementia.
Fazekas scores are more easily measured than WMH
volumes. However, calculation of the sample size for
scales such as the Fazekas scale is more complex and re-
quires data that may not be readily available. The results
shown in Table 3 suggest that the sample size is sensitive
to small changes in the assumed OR—a small decrease
in OR of just 0.04 caused the sample size to more than
double, and a small increase in OR of 0.05 more than
halved the number. Therefore, researchers should use
the most precise estimates available to ensure than any
ordinal logistic regression analysis is suitably powered.
Also, sample size may counterintuitively increase when
estimates are adjusted for baseline covariates [45]. Even
so, it is recommended that researchers use adjustment
in logistic regression both to balance the trial groups for
important outcome predictors and to have estimates that
are more readily applicable to individual patients [34]. Re-
searchers need to undertake a simulation study to explore
assumptions and the sensitivity of the estimated sample
size to those assumptions. A compromise for the signifi-
cant organisational effort, cost and ‘noise’ involved in
assessing baseline WMH volume that captures the similar
prognostic information might be to use the baseline Faze-
kas score and adjust for covariates and use WMH volumes
as outcome. It is also important to tie WMH to a relevant
clinical outcome such as cognition, recurrent stroke, other
vascular events or death, and possibly a measure of mobil-
ity, to capture the physical effects of small vessel disease.
In our statistical model, we used raw WMH volumes
and checked model performance by examining residual
behaviour and linearity assumptions. Some aspects of
model performance were improved by using the loga-
rithm of the WMH volumes rather than the raw data.
The greatest improvements occurred when we used log-
arithms for both baseline and follow-up data. In our
opinion, the improvement in model performance with
logged data was not great, so we chose to present results
for the raw data for ease of interpretation. However, we
recognize that this is a subjective choice and that others
might choose differently. Unsurprisingly, the models
with raw and logged data all revealed baseline WMH to
be positively related to follow-up WMH, with high R2
values of 0.90 for raw baseline and follow-up and 0.87
for logged baseline and follow-up. Therefore, the reduc-
tion in sample size would be similar, regardless of
whether logged or raw data were used.
Although our sample size for the comparison of me-
dians gave an unachievable sample size (174,432 before
allowing for dropouts), this does not mean that analysis
with medians in other contexts is unfeasible. Researchers
wishing to use medians could explore the non-
parametric ANCOVA models with simulation studies,
not only to estimate sample size but also to test the suit-
ability of the ANCOVA models for the kind of data they
are likely to obtain. This is beyond the scope of this
paper, but it could be a subject for further research.
We show, in a fairly typical population of patients pre-
senting to a regional hospital with non-disabling stroke
and managed according to current UK guidelines with
anti-hypertensives, statins, antiplatelet drugs and lifestyle
advice, that WMH may decrease, stay the same and in-
crease over the course of 1 year after stroke. Baseline
MAP was inversely associated with WMH volume in
multivariate analyses. This is counterintuitive, but it may
have occurred if patients with higher initial MAP were
diagnosed when presenting to the stroke clinic and were
started on anti-hypertensive medication, or if they
already had a diagnosis of hypertension but were not
taking their prescribed anti-hypertensive medications
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and were motivated by their stroke to take their medica-
tions, leading to better blood pressure control, which may
have contributed to reducing the development of WMH.
In general, WMH are assumed only to increase in size, but
the fact that they may decrease as shown here (in 35%)
adds to the variation in follow-up volumes, thus inflating
sample sizes, and indicates that they do not consist only of
permanently damaged tissue. However, it would seem that
WMHs are much more dynamic, at least in the year after
mild stroke, than previously thought. Reasons for this dy-
namic WMH change, as well as the primary mechanisms
underlying WMH, should be determined urgently.
Conclusions
Sample sizes for RCTs using WMH as an outcome can
vary enormously according to measurement of WMH, ad-
justment for predictors, and method of analysis. Smaller
sample sizes will be obtained in studies that use WMH
volumes rather than Fazekas scores, but measuring vol-
umes is resource-intensive. Dropout rates and scanner
drift could impact results. Triallists undertaking studies
using WMH as an outcome need to consider their study
design and analysis plan carefully to maximise efficiency.
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